Biocompatibles has agreed to be acquired by BTG for £177.2 M (US$283 M) in a cash and share deal to create an international speciality healthcare company. Biocompatibles’ interventional oncology businesses represent a good strategic fit with BTG’s portfolio of specialist hospital products. Former Biocompatibles shareholders will hold 21.1% of the share capital of the enlarged group.